Medicinova Inc MNOV
We take great care to ensure that the data presented and summarized in this overview for MEDICINOVA INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MNOV
View all-
Essex Woodlands Management, Inc. The Woodlands, TX1.11MShares$2.02 Million0.54% of portfolio
-
Black Rock Inc. New York, NY695KShares$1.27 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA623KShares$1.14 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA515KShares$942,2920.0% of portfolio
-
Citigroup Inc502KShares$918,5810.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA251KShares$460,0250.0% of portfolio
-
Ubs Group Ag223KShares$407,6100.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny181KShares$331,7790.0% of portfolio
-
State Street Corp Boston, MA175KShares$319,5140.0% of portfolio
-
Bank Of America Corp Charlotte, NC161KShares$295,2000.0% of portfolio
Latest Institutional Activity in MNOV
Top Purchases
Top Sells
About MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Insider Transactions at MNOV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 28
2022
|
Hideki Nagao Director |
SELL
Open market or private sale
|
Direct |
6,754
-100.0%
|
$13,508
$2.25 P/Share
|
|
Nov 22
2022
|
Hideki Nagao Director |
SELL
Open market or private sale
|
Direct |
218
-3.13%
|
$436
$2.13 P/Share
|
|
Nov 21
2022
|
Hideki Nagao Director |
SELL
Open market or private sale
|
Direct |
5,365
-43.49%
|
$10,730
$2.18 P/Share
|
|
Nov 17
2022
|
Hideki Nagao Director |
SELL
Open market or private sale
|
Direct |
309
-2.44%
|
$618
$2.18 P/Share
|
|
Aug 23
2021
|
Kazuko Matsuda Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+15.67%
|
$120,000
$2.3 P/Share
|
|
Jul 09
2021
|
Yuichi Iwaki President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
39,583
+3.93%
|
$79,166
$2.54 P/Share
|
|
Jun 24
2021
|
Kazuko Matsuda Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
102,804
+18.0%
|
$205,608
$2.5 P/Share
|
|
May 19
2021
|
Geoffrey O Brien Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
43,318
+32.68%
|
$86,636
$2.5 P/Share
|
|
Mar 11
2021
|
Hideki Nagao Director |
SELL
Open market or private sale
|
Direct |
2,354
-15.69%
|
$16,478
$7.4 P/Share
|
|
Feb 25
2021
|
Yuichi Iwaki President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
86,250
+8.51%
|
$172,500
$2.46 P/Share
|